Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries no "tag".
The protein has a calculated MW of 62.6 kDa. The protein migrates as 60 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Supplied as 0.2 μm filtered solution in 12.5 mM Citric acid, pH6.2 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Recombinant Fibronectin fragment, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) was greater than 90% as determined by SEC-HPLC.
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) immobilized on SA Chip can bind Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) with a typical affinity constant of 0.547 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Biotinylated Human ITGA5&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82Wa) immobilized on SA Chip can bind Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) with a typical affinity constant of 38.2 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) immobilized on CM5 Chip can bind Heparin Sulfate with a typical affinity constant of 0.103 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) could promote mesenchymal stem cell attachment and proliferation in several passages, comparable with Competitor T. The bioactivity of Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) is similar to GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18).
Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) could maintain the stemness of MSC in several passages, with high expression of MSC markers CD73, CD90 and CD105 and negative expression of HLA-DR, CD34 and CD45. The stemness ability of Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) is comparable with Competitor T and similar to GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18).
2e5 Jurkat cells were transfected with pLenti-CMV-EGFP-puro-Amp for 48 hours in the presence or absence of Fibronectin fragment, premium grade (Cat. No. FIN-H5116)-coated. The GFP fluorescence was detected with FACS. The Alexa Fluor 488 signal was used to evaluate the expression of GFP+ Jurkat cells (Routinely tested).
CD34+ CD45+ hematopoietic cells were seeded on GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) combined with GMP Human DLL4 Protein, Fc Tag (Flagship) (Cat. No. GMP-DL4H27) and GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) coated plates and differentiated for 21 days, then flow cytometry was used to detect the expression of T-cell progenitor markers, CD5 and CD7. GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) combined with GMP Human DLL4 Protein, Fc Tag (Flagship) (Cat. No. GMP-DL4H27) and GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) can induce the formation of CD7+ and CD5+ CD7+ T-cell progenitors. The bioactivity of GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) is similar to Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116), as well as the competitor T. Negative control: w/o Human Fibronectin.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Eye Diseases; Venous Thrombosis; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Onfekafusp alfa | Phase 3 Clinical | Philogen Spa | Solid tumours; Glioblastoma; Sarcoma; Breast Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Glioma; Lung Neoplasms; Melanoma | Details | |
Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Adenomatous Polyposis Coli; Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Radretumab | L19-I131; L19-SIP; I-L19-SIP; I-131-L19-SIP; 131I-L19-SIP; L19-131-I; 131I-radretumab; 131I-L19SIP; L19-131I | Phase 2 Clinical | Philogen Spa | Hematologic Neoplasms; Hodgkin Disease; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
PYX-201 | PYX-201 | Phase 2 Clinical | Pfizer Inc | Solid tumours | Details |
F8-IL10 | F8-IL10; PF-06687234 | Phase 2 Clinical | Philogen Spa | Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative | Details |
177Lu-B5-IgG4 | 177-Lu-B5-IgG4 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Solid tumours | Details |
This web search service is supported by Google Inc.